Literature DB >> 7686602

Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside.

G S Yang1, M D Minden, E A McCulloch.   

Abstract

Regulatory molecules that affect the growth culture of blast cells from acute myeloblastic leukemia (AML) may also alter drug sensitivity, a phenomenon that may be called regulated drug sensitivity. Previous studies have shown: (i) blast cells exposed to retinoic acid before cytosine arabinoside (Ara-C) usually show increased sensitivity, but after some retinoic acid exposure times, sensitivity may be decreased; (ii) factor-sensitive or responsive blasts cultured with granulocyte colony-stimulating factor (G-CSF) are regularly more Ara-C-sensitive than when cultured with granulocyte-macrophage CSF (GM-CSF). This paper is concerned with the effects of schedule on drug sensitivity as regulated by either retinoic acid or the myelopoietic growth factors, G-CSF and GM-CSF. We measured the effects of retinoic acid on the sensitivity of blasts cells from the two continuous AML lines to Ara-C or arabinofuranosyl 5-azacytosine (Ara-AC). Cells from seven patients with AML were tested for Ara-C sensitivity in conjunction with retinoic acid. The cells were treated with retinoic acid before or after administration of the drug. Both increases and decreases in Ara-C sensitivity were seen for both schedules. Consistent increases in Ara-C sensitivity were obtained when retinoic acid was included in the methylcellulose cultures used to determine clonogenic cell recovery at each drug dose. In studies of growth factors, a single factor-dependent cell line (OCI/AML-5) was used to compare the effects of G-CSF and GM-CSF on Ara-C sensitivity. An experimental design was used that permitted factors to present in culture for 24 h before Ara-C, during the next 24 h period with the drug, for a subsequent day in suspension without drug, and during the 5-7 days required for colony formation in methylcellulose cultures. G-CSF and GM-CSF were most effective in increasing or decreasing Ara-C, respectively, when the factor under test was included in the methylcellulose cultures. Thus, like retinoic acid, growth factors influenced drug sensitivity when they were present after the drug had been removed. These data, therefore, are compatible with the hypothesis that repair mechanism may contribute to regulated drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686602

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.

Authors:  C Ustün; M Beksac; K Dalva; H Koc; N Konuk; O Ilhan; M Ozcan; P Topcuoglu; D Sertkaya; M Hayran
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

3.  Early Detection of t(8;21) Chromosomal Translocations During Treatment of PML-RARA Positive Acute Promyelocytic Leukemia: A Case Study.

Authors:  Walter Kleine Neto; Mariana Serpa; Sabri Saeed Sanabani; Patricia Torres Bueno; Elvira Deolinda Rodrigues Pereira Velloso; Pedro Enrique Dorlhiac-Llacer; Israel Bendit
Journal:  Clin Med Insights Oncol       Date:  2010-12-20

4.  SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.

Authors:  Adi Zipin-Roitman; Nasma Aqaqe; Muhammad Yassin; Shahar Biechonski; Mariam Amar; Mark F van Delft; Olga I Gan; Sean P McDermott; Alla Buzina; Troy Ketela; Liran Shlush; Stephanie Xie; Veronique Voisin; Jason Moffat; Mark D Minden; John E Dick; Michael Milyavsky
Journal:  Oncotarget       Date:  2017-03-07

5.  MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.

Authors:  Gautam Borthakur; Seshagiri Duvvuri; Vivian Ruvolo; Durga Nand Tripathi; Sujan Piya; Jared Burks; Rodrigo Jacamo; Kensuke Kojima; Peter Ruvolo; Juan Fueyo-Margareto; Marina Konopleva; Michael Andreeff
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

6.  All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Authors:  Richard F Schlenk; Michael Lübbert; Axel Benner; Alexander Lamparter; Jürgen Krauter; Wolfgang Herr; Hans Martin; Helmut R Salih; Andrea Kündgen; Heinz-A Horst; Peter Brossart; Katharina Götze; David Nachbaur; Mohammed Wattad; Claus-Henning Köhne; Walter Fiedler; Martin Bentz; Gerald Wulf; Gerhard Held; Bernd Hertenstein; Hans Salwender; Verena I Gaidzik; Brigitte Schlegelberger; Daniela Weber; Konstanze Döhner; Arnold Ganser; Hartmut Döhner
Journal:  Ann Hematol       Date:  2016-10-03       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.